This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Umemura, M.
Right arrow Articles by Yoshikai, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Umemura, M.
Right arrow Articles by Yoshikai, Y.

 Previous Article  |  Next Article 

Journal of Virology, September 2000, p. 8226-8233, Vol. 74, No. 18
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Expression of Mouse Mammary Tumor Virus Superantigen Accelerates Tumorigenicity of Myeloma Cells

Masayuki Umemura,1 Worawidh Wajjwalku,2 Narin Upragarin,2 Tie Liu,1 Hitoshi Nishimura,1 Tetsuya Matsuguchi,1 Yukihiro Nishiyama,3 Gary M. Wilson,4 and Yasunobu Yoshikai1,*

Laboratory of Host Defense1 and Laboratory of Virology,3 Research Institute for Disease Mechanism and Control, Nagoya University School of Medicine, Nagoya 466-8550, Japan; Department of Pathology, Faculty of Veterinary Medicine, Kasetsart University, Nakhonpathom, Thailand2; and The Howard Hughes Medical Institute, Division of Basic Immunology, Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado 802064

Received 20 January 2000/Accepted 10 June 2000

To investigate whether superantigen (SAG) from endogenous mouse mammary tumor virus functions as an immunogenic or a tumorigenic factor in tumor development, the BALB/c myeloma cell line FO was transfected with the SAG gene from the 3' Mtv-50 long terminal repeat (LTR) open reading frame (ORF), the product of which was specific for Vbeta 6. All five transfectants expressing Mtv-50 LTR ORF mRNA showed stimulatory activity for Vbeta 6 T-cell hybridomas in vitro; this activity was inhibited by the addition of anti-Mtv-7 monoclonal antibody (MAb) or anti-major histocompatibility complex class II I-Ad and I-Ed MAb. All transfectants with the SAG gene grew more rapidly than did mock transfectants in BALB/c mice after subcutaneous inoculation, whereas all clones, including mock transfectants, grew equally well in athymic nude mice. A significant fraction of Vbeta 6 T cells selectively expressed activation markers, including CD44high, CD62Llow, and CD69high, and produced large amounts of interleukin 5 (IL-5) and IL-6 in BALB/c mice inoculated with transfectants. These results suggested that the expression of viral SAG enhances the tumorigenicity of a myeloma cell line through the stimulation of SAG-reactive T cells.


* Corresponding author. Mailing address: Laboratory of Host Defense, Research Institute for Disease Mechanism and Control, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. Phone: 81-52-744-2446. Fax: 81-52-744-2449. E-mail: yyoshika{at}med.nagoya-u.ac.jp.


Journal of Virology, September 2000, p. 8226-8233, Vol. 74, No. 18
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.